Corpus Intelligence IC Memo — RESTON HOSPITAL 2026-04-26 03:50 UTC
IC Memo — RESTON HOSPITAL
Investment Committee Memorandum | VA | 201 beds | Grade C | EBITDA uplift $28.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

RESTON HOSPITAL

CCN 490107 | FAIRFAX, VA | 201 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

RESTON HOSPITAL is a 201-bed suburban community hospital in FAIRFAX, VA with $385.5M in net patient revenue and a 34.6% operating margin. The hospital serves a payer mix of 27.1% Medicare, 6.5% Medicaid, and 66.4% commercial.

Thesis: Platform Growth. Our ML models identify $28.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 34.6% to 42.0% (+736bps).

Net Revenue HCRIS$385.5M
Current EBITDA COMPUTED$133.4M
Operating Margin COMPUTED34.6%
Occupancy HCRIS72.3%
Revenue / Bed COMPUTED$1.9M
Net-to-Gross HCRIS20.4%
Distress Probability ML41.8%

2. Market Context & Competitive Position

111
VA Hospitals
4.4%
State Median Margin
39
Comparable Hospitals

VA has 111 Medicare-certified hospitals with a median operating margin of 4.4%. The target's margin of 34.6% places it above the state median. Among 39 size-comparable peers (100-402 beds), the median margin is 5.2%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (100-402), prioritizing same-state peers. 39 hospitals in the comp set.

HospitalStateBedsRevenueMargin
RESTON HOSPITAL (Target)VA201$385.5M34.6%
RIVERSIDE REGIONAL MEDICAL CENVA379$963.3M-20.1%
ST. MARYS HOSPITALVA363$688.9M13.3%
VIRGINIA HOSPITAL CENTER ARLINVA336$624.4M1.8%
CHILDRENS HOSPITAL OF THE KINGVA202$546.2M-9.9%
SENTARA LEIGH HOSPITALVA274$511.5M14.7%
INOVA LOUDOUN HOSPITAL CENTERVA189$510.3M22.9%
INOVA ALEXANDRIA HOSPITALVA303$456.5M26.3%
SENTARA VA. BEACH GENERAL HOSPVA239$443.9M15.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $28.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$8.1M+210bp18mo
Cost to Collect4.5%2.5%$7.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$7.6M+198bp12mo
A/R Days Reduction5200.0%3800.0%$4.7M+122bp9mo
Clean Claim Rate88.0%96.0%$247K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$8.1M
Cost to Collect
$7.7M
Denial Rate Reduction
$7.6M
A/R Days Reduction
$4.7M
Clean Claim Rate
$247K
Total EBITDA Uplift$28.4M
Current EBITDA$133.4M
+ RCM Uplift+$28.4M
Pro Forma EBITDA$161.8M
Current Margin34.6%
Pro Forma Margin42.0%
WC Released (1x)$14.8M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$205.2M$1.16B5.67x41.5%
Base (11x exit)10.0x11.0x$205.2M$1.35B6.56x45.7%
Bull Case9.0x11.0x$184.7M$1.51B8.16x52.2%
Bull (12x exit)9.0x12.0x$184.7M$1.70B9.20x55.9%
Bear Case11.0x10.0x$225.7M$955.0M4.23x33.4%
Bear (11x exit)11.0x11.0x$225.7M$1.12B4.98x37.9%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 39 hospitals with 100-402 beds
  • Same-state prioritization (n=40)
  • Comp margins: P25=-4.1% / P50=5.2% / P75=14.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.